Abstract：Objective: To explore the expression of miR-187 in the tissues of lung cancer and its effect. Methods: By normalized to U6, the expressions of miR-187 in 32 lung cancer and matched non-tumor adjacent tissue specimens were examined by stem-loop real-time RT-qPCR method. The relationship between miR-187 expression and clinicopathological characteristics was further analyzed. After transfected with miR-187 mimics, the biological functions of miR-187 were determined by cell proliferation and cell cycle assay. Results: Expression of miR-187 in the tissue of lung cancer was obviously higher than that in non-tumor adjacent tissue specimens (t=5.236, P<0.0001). Clinical features correlation analysis showed that the down-expression of miR-187 was correlated with the pathological grading and the clinical staging (P<0.05). Functional studies indicated that the overexpression of miR-187 dramatically inhibited the proliferation of A549 cells in vitro and changed the situation of the cell cycle, arrested at G0/G1 phase. Conclusion: Down-expression of miR-187 in the patients of lung cancer may play a key role in the development and progression of lung cancer.
[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] ZHAO P, DAI M, CHEN W, et al. Cancer trends in China[J].Jpn J Clin Oncol, 2010, 40: 281-285.
[3] Li S, Gao M, Li Z, et al. Role of microRNAs in metassis of non-small cell lung cancer[J]. Front Biosci (LandmarkEd), 2016(1), 21: 1.
[4] ANGULO M, LECUONA E, SZNAJDER J I. Role of microRNAs in lung disease[J]. Arch Bronconeumol, 2012, 48(9): 325-330.
[5] Ha T Y. MicroRNAs in human diseases: from lung, liver and kidney diseases to infectious disease, sickle cell disease and endometrium disease[J]. Immune Netw, 2011, 11(6): 309-323.
[6] OGLESBY I K, MCELVANEY N G, GREENE C M. MicroRNAs in inflammatory lung disease—master regulators or target practice?[J]. Respir Res, 2010, 11: 148.
[7] ZAMORE P D, HALEY B. Ribo-gnome: the big world of small RNAs[J]. Science, 2005, 309(2): 1519-1524.
[8] CALIN G A, DUMITRU C D, SHIMIZU M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J].Proc Natl Acad Sci U S A, 2002, 99(24): 15524-15529.
[9] CHEN H, CHEN G, CHEN Y, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma[J]. Br J Cancer, 2009, 100: 1002-1011.
[10] FRIDMAN E, DOTAN Z, BARSHACK I, et al. Accurate molecular classification of renal tumors using microRNA expression[J]. J Mol Diagn, 2010, 12(5): 687-696.
[11] BLOOMSTON M, FRANKEL W L, PETROCCA F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA, 2007, 297: 1901-1908.
[12] NIKIFOROVA M N, TSENG G C, STEWARD D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility[J]. J Clin Endocrinol Metab, 2008, 93(5): 1600-1608.
[13] WIJNHOVEN B, HUSSEY D J, WATSON D I, et al. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma[J]. Br J Surg, 2010, 97: 853-861.
[14] CHEN Y, STALLINGS R L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis[J]. Cancer Res, 2007,67(3): 976-983.
[15] CHAO A, LIN C, LEE Y, et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2[J]. Oncogene, 2011, 31(6): 764-775.
[16] MULRANE L, MADDEN S F, BRENNAN D J, et al. miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro[J]. Clin Cancer Res, 2012, 18(24): 6702-6713.
[17] CHENG A M, BYROM M W, SHELTON J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis[J]. Nucleic Acids Res, 2005, 33(4): 1290-1297.
[18] PARK S Y, LEE J H, HA M, et al. miR-29 miRNAs activate p53 by targeting p85α and CDC42[J]. Nat Struct Mol Biol,2008, 16(1): 23-29.
[19] SIROTKIN A V, LAUKOVÁ M, OVCHARENKO D, et al. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis[J]. J Cell Physiol, 2010, 223: 49-56.
[20] HELWAK A, KUDLA G, DUDNAKOVA T, et al. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding[J]. Cell, 2013, 153(3): 654-665.
[21] RIMKUS C, FRIEDERICHS J, ROSENBERG R, et al. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer[J]. Int J Cancer, 2007,120(1): 207-211.
[22] CAO W, ZHANG B, LIU Y, et al. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival[J]. Am J Clin Pathol, 2007, 128(3): 430-436.
[23] CAO W F, ZHANG L Y, LIU M B, et al. Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray[J]. Hum Pathol, 2007, 38(5): 747-752.
[24] WANG Y, CAO W, YU Z, et al. Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents[J]. Cancer Biol Ther, 2009, 8(17): 1651-1658.
[25] ZHANG L, DING F, CAO W, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma[J]. Clin Cancer Res, 2006, 12(5): 1639-1646.
